We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Urine Test Uses Tiny Worms to Detect Early Signs of Cancer

By LabMedica International staff writers
Posted on 24 Nov 2021
Image: Nematodes used in N-NOSE (Photo courtesy of Hirotsu Bio Science)
Image: Nematodes used in N-NOSE (Photo courtesy of Hirotsu Bio Science)

Scientists have developed a screening test that uses tiny worms to detect early signs of cancer in urine that could help boost routine screening.

Scientists at Hirotsu Bio Science (Tokyo, Japan) have developed N-NOSE, a cancer screening test that uses highly sensitive olfactory sensory functions of genetically modified a type of worm called "C. elegans" (nematodes) with an acute sense of smell. N-NOSE, which stands for Nematode Nose, uses the chemotaxis characteristic of nematodes, i.e., attractive responses to an odor it likes and repulsive responses to an odor it does not like, as an indicator. Nematodes are known to respond to 15 types of cancer of the stomach, colorectal, lung, breast, pancreatic, liver, prostate, uterine, esophageal, gall bladder, bile duct, kidney, bladder, ovarian, and oral/pharyngeal.

C. elegans nematode is the first multicellular organism to have its entire genome sequenced and is a very popular model organism in biological research. The idea of using nematodes, live creatures, in cancer testing stems from the fact that they have superior olfactory sensors that no man-made device can come close to. Because it has no eyes or ears, it relies on smell to navigate its environment and detect food. C. elegans therefore has a well-developed sense of smell and about 1,200 types of olfactory receptor genes that are able to detect minute odors that machines cannot detect. The novel N-NOSE test that employs the worm’s natural capabilities is not invasive, causes no pain and can be used for early detection of cancer.

The test requires a small amount of urine and is inexpensive since nematodes are inexpensive to breed. Each nematode lays as many as 300 eggs and feeds on coliform bacterium E. coli, making it inexpensive to breed C. elegans populations. Currently available cancer diagnostic tests often do not detect incipient cancer and it has been thought very difficult to know the existence of cancer at an early stage. However, nematodes respond to the minute odor of cancer, which is undetectable with existing tests, and thus make it possible to predict risks. Early detection of cancers as early as Stages 0 and 1 is possible with N-NOSE according to clinical studies, and one test is able to detect cancers regardless of their locations. The simple, painless urine test is suitable as a cancer test for all generations, including children. The company believes that in future, children will take regular cancer screening tests to detect pre-symptomatic tumors.

Related Links:
Hirotsu Bio Science 

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Clinical Informatics Platform
CLARION™
Thyroid Test
Anti-Thyroid EIA Test

Channels

Molecular Diagnostics

view channel
Image: A research team led by Prof. Hsing I-Ming (center), Professor of the Department of Chemical and Biological Engineering at HKUST, has developed TEMPO, a thermodynamically programmed one-pot CRISPR platform for rapid, point-of-care nucleic acid testing. Mr. Wu Xiaolong (third right) and Ms. Li Yanan (first left), PhD students from the Department of Chemical and Biological Engineering, are the co-first authors of this study. (Photo courtesy of HKUST)

Single-Tube CRISPR Test Detects Pathogens and Genetic Variants in 30 Minutes

Rapid, accurate detection of infectious agents and single-nucleotide variants remains difficult to deliver outside centralized laboratories. Although multi-step nucleic acid workflows are sensitive, they... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification

Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Journal Addresses Evolving Needs in Clinical and Translational Pathology

Clinical pathology underpins diagnosis and therapy selection across oncology and other major diseases, but the field is rapidly evolving as new technologies reshape how disease is studied and classified.... Read more